Az ibandronát helye a postmenopausalis osteoporosis kezelésében

Translated title of the contribution: Ibandronate in the treatment of postmenopausal osteoporosis

Research output: Contribution to journalArticle

Abstract

Postmenopausal osteoporosis affects 7-10% of the population of developed countries. During the past decade, a number of new therapeutical modalities have been made available. Among these, bisphosphonates mean the mainstay of medical treatment. Ibandronate belongs to the amino-bisphosphonate group of these drugs. Amino-bisphosphonates act via the mevalonate metabolic pathway, thus, inhibiting protein prenylation. Several clinical studies have shown a significant reduction in the fracture risk of osteoporotic patients treated with ibandronate. This compound can be administered orally once a month or intravenously once in every 3 months. Longer dosing intervals stimulate patient compliance, and consequently increase efficacy and cost effectiveness.

Original languageHungarian
Pages (from-to)657-661
Number of pages5
JournalLege Artis Medicinae
Volume18
Issue number10
Publication statusPublished - Oct 2008

Fingerprint

Postmenopausal Osteoporosis
Diphosphonates
Protein Prenylation
Mevalonic Acid
Fracture Fixation
Osteoporotic Fractures
Patient Compliance
Metabolic Networks and Pathways
Developed Countries
Cost-Benefit Analysis
Therapeutics
Pharmaceutical Preparations
Population
ibandronic acid

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Az ibandronát helye a postmenopausalis osteoporosis kezelésében. / Lakatos, P.

In: Lege Artis Medicinae, Vol. 18, No. 10, 10.2008, p. 657-661.

Research output: Contribution to journalArticle

@article{866fc0f672db42f8b38f5921e5ad4552,
title = "Az ibandron{\'a}t helye a postmenopausalis osteoporosis kezel{\'e}s{\'e}ben",
abstract = "Postmenopausal osteoporosis affects 7-10{\%} of the population of developed countries. During the past decade, a number of new therapeutical modalities have been made available. Among these, bisphosphonates mean the mainstay of medical treatment. Ibandronate belongs to the amino-bisphosphonate group of these drugs. Amino-bisphosphonates act via the mevalonate metabolic pathway, thus, inhibiting protein prenylation. Several clinical studies have shown a significant reduction in the fracture risk of osteoporotic patients treated with ibandronate. This compound can be administered orally once a month or intravenously once in every 3 months. Longer dosing intervals stimulate patient compliance, and consequently increase efficacy and cost effectiveness.",
keywords = "Bisphosphonates, Dosing regimes, Fracture risk reduction, Ibandronate, Osteoporosis",
author = "P. Lakatos",
year = "2008",
month = "10",
language = "Hungarian",
volume = "18",
pages = "657--661",
journal = "Lege Artis Medicinae",
issn = "0866-4811",
publisher = "Literatura Medica Publishing House",
number = "10",

}

TY - JOUR

T1 - Az ibandronát helye a postmenopausalis osteoporosis kezelésében

AU - Lakatos, P.

PY - 2008/10

Y1 - 2008/10

N2 - Postmenopausal osteoporosis affects 7-10% of the population of developed countries. During the past decade, a number of new therapeutical modalities have been made available. Among these, bisphosphonates mean the mainstay of medical treatment. Ibandronate belongs to the amino-bisphosphonate group of these drugs. Amino-bisphosphonates act via the mevalonate metabolic pathway, thus, inhibiting protein prenylation. Several clinical studies have shown a significant reduction in the fracture risk of osteoporotic patients treated with ibandronate. This compound can be administered orally once a month or intravenously once in every 3 months. Longer dosing intervals stimulate patient compliance, and consequently increase efficacy and cost effectiveness.

AB - Postmenopausal osteoporosis affects 7-10% of the population of developed countries. During the past decade, a number of new therapeutical modalities have been made available. Among these, bisphosphonates mean the mainstay of medical treatment. Ibandronate belongs to the amino-bisphosphonate group of these drugs. Amino-bisphosphonates act via the mevalonate metabolic pathway, thus, inhibiting protein prenylation. Several clinical studies have shown a significant reduction in the fracture risk of osteoporotic patients treated with ibandronate. This compound can be administered orally once a month or intravenously once in every 3 months. Longer dosing intervals stimulate patient compliance, and consequently increase efficacy and cost effectiveness.

KW - Bisphosphonates

KW - Dosing regimes

KW - Fracture risk reduction

KW - Ibandronate

KW - Osteoporosis

UR - http://www.scopus.com/inward/record.url?scp=55549100295&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55549100295&partnerID=8YFLogxK

M3 - Article

VL - 18

SP - 657

EP - 661

JO - Lege Artis Medicinae

JF - Lege Artis Medicinae

SN - 0866-4811

IS - 10

ER -